


Amaxa™ HT Nucleofector™ protocol for K562 (ATCC®)

Cell description

Human chronic myelogenous leukemia cell line; lymphoblastoid cells; (ATCC® CCL-243™, cryopreserved).

Example for Nucleofection™ of K562 cells



Transfection efficiency of K562 cells 24 hours post Nucleofection™. K562 cells (ATCC® CCL-243™) were transfected with program FF-120-DA and 0.4 µg of pmaxGFP™ Vector. 24 hours post Nucleofection™ cells were analyzed on a FACSCalibur™ with HTS option (Becton Dickinson). Cell viability (% PI negative cells) is usually around 95% after 24 hours.

Product description

Recommended kits

SF cell line HT Nucleofector™ kit

Cat. No.	V5SC-2002
Size (reactions)	2×384
SF cell line HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate(s)	2

Cat. No.	V5SC-2010
Size (reactions)	10×384
SF cell line HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate(s)	10

Storage and stability

Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long-term storage, pmaxGFP™ vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution, it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT Nucleofector™, the 96-well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

Required material

Note

Please make sure that the entire supplement is added to the Nucleofector™ solution

- HT Nucleofector™ system
- Supplemented HT Nucleofector™ solution at room temperature
- Supplied 384-well Nucleocuvette™ plate(s)
- Supplied pmaxGFP™ vector, stock solution 1 µg/µl

Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration

- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260 : A280 ratio should be at least 1.8
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S. (US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266), Matrix TallTips™ (Matrix Technologies Corp., Cat. No. 7281) or LTS Tips (Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S). Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- 384-well culture plates or culture plates of your choice
- Culture medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 90 % [ATCC®, Cat. No. 30-2005]; fetal bovine serum, 10 %
- Prewarm appropriate volume of culture medium to 37°C (91 µl per sample)
- Appropriate number of cells (2×10⁵ cells per sample; 2.5×10³ cells can be used with slightly reduced viability. At even lower cell numbers viability is strongly decreased)

1. Pre Nucleofection™

Cell culture recommendations

- 1.1 Replace media every 2–3 days
- 1.2 Passage cells after reaching 1×10⁶ cells/ml. Do not use cells after passage 10 for Nucleofection™
- 1.3 Seed out 1×10⁵ cells/ml
- 1.4 Subculture 2 days before Nucleofection™ at a density of 3×10⁵ cells/ml. Higher cell densities may cause lower Nucleofection™ efficiencies

2. Nucleofection™

One Nucleofection™ sample contains

- 2×10⁵ cells
 - 0.2–1 µg plasmid DNA (in 1–2 µl H₂O or TE) or 0.4 µg pmaxGFP™ vector or 30–300 nM siRNA (0.6–6 pmol/sample)
 - 20 µl SF cell line HT Nucleofector™ solution
- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
 - 2.2 Start HT Nucleofector™ software, verify device connection and upload experimental parameter file (for details refer to the HT Nucleofector™ manuals)
 - 2.3 Select the appropriate HT Nucleofector™ program **FF-120-DA**
 - 2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media, e.g. 51 µl* (see note at the end of this chapter) for one well of a 384-well plate and pre-incubate/equilibrate plates in a humidified 37°C/5 % CO₂ incubator
 - 2.5 Pre-warm an aliquot of culture medium to 37°C (40 µl per sample)
 - 2.6 Prepare 0.2–1 µg plasmid DNA or 0.4 µg pmaxGFP™ vector or 30 nM–300 nM siRNA (0.6–6 pmol/sample)
 - 2.7 Count an aliquot of the cells and determine cell density
 - 2.8 Centrifuge the required number of cells (2×10⁵ cells per sample) at 90×g for 10 minutes at room temperature. Remove supernatant completely
 - 2.9 Resuspend the cell pellet carefully in 20 µl room temperature HT Nucleofector™ solution per sample

A: One or several substrates (DNAs or RNAs) in multiples

- Prepare mastermixes by dividing cell suspension according to number of substrates
- Add required amount of substrates to each aliquot (max. 2 µl per sample)
- Transfer 20 µl of mastermixes into the wells of the 384-well Nucleocuvette™ plates

B: Multiple substrates (e.g. library transfection)

- Pipette 20 µl of cell suspension into each well of a sterile U-bottom 384-well microtiter plate
- Add 2 µl substrates (maximum) to each well
- Transfer 20 µl of cells with substrates into the wells of the 384-well Nucleocuvette™ plates

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a liquid handling system or at least a multi-channel pipette with suitable pipette tips. As leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.10 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and the sides of the wells without airbubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate
- 2.11 Place 384-well Nucleocuvette™ plate with closed lid onto the carousel of the plate handler of the HT Nucleofector™. Well "A1" must be in upper left position
- 2.12 Start Nucleofection™ process clicking "Start" in the HT Nucleofector™ software (for details refer to the HT Nucleofector™ manuals)
- 2.13 After run completion, carefully remove the 384-well Nucleocuvette™ plate from the carousel
- 2.14 Resuspend cells with desired volume of pre-warmed culture medium (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for 384-well plates: Resuspend cells in 40 µl of pre-warmed media*
- 2.15 Plate desired amount of cells in culture system of your choice. Recommendation for 384-well plates: Transfer 9 µl of resuspended cells to 51 µl pre-warmed media

* Note

The indicated cell numbers and volumes have been found to produce optimal Nucleofection™ results in most cases. However, depending on your specific needs you may wish to test an extended range of cell numbers. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded.

3. Post Nucleofection™

- 3.1 Incubate the cells in humidified 37°C/5 % CO₂ incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4–8 hours

Additional information

Up-to-date List of all Nucleofector™ references

www.lonza.com/nucleofection-citations

Technical assistance and scientific support

USA/Canada

Tel 800 521 0390 (toll-free)

Fax 301 845 8338

scientific.support@lonza.com

Europe and Rest of World

Tel + 49 221 99199 400

Fax + 49 221 99199 499

scientific.support.eu@lonza.com

www.lonza.com

Lonza Cologne GmbH – 50829 Cologne, Germany

Please note that the Amata™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system, 96-well Nucleocuvette™ plates and modules, HT Nucleofector and 384-well Nucleocuvette plates is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. Amata, Nucleofector, Nucleofection, 96-well Shuttle, Nucleocuvette and maxGFP are either registered trademarks or trademarks of the Lonza Cologne GmbH in Germany and/or U.S. and/or other countries. ATCC® and the ATCC Catalog Marks are trademarks of ATCC. Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242. The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license. No statement is intended or should be construed as a recommendation to infringe any existing patent.